first
First Cannabis full-spectrum product, manufactured in Brazil by Ease Labs, is approved by the local Health Regulatory Agency
- It is the first full-spectrum extract manufactured locally and approved by the regulatory agency;
- Studies indicate that the product may bring benefits in the treatment of fibromyalgia, dementia and chronic pain.
SÃO PAULO, Jan. 24, 2024 /PRNewswire/ — Ease Labs Pharma, a GMP Certified Pharmaceutical Company pioneer in the Cannabis market in Brazil, has just received the approval from the Brazilian Health Regulatory Agency to commercialize the Cannabis sativa Extract locally, containing 750mg (25mg/mL) of CBD, up-to 0.2% THC, and other cannabinoids – a full-spectrum extract, that was developed and formulated at the pharmaceutical facility, located in Belo Horizonte (MG). The product will be available for sale in pharmacies, with a medical prescription, from March this year.
Brazil’s current regulation for pharmaceutical Cannabis was approved in 2019, which classifies cannabinoids as pharmaceutical drugs, and requires complex safety data and restricted pharmaceutical certifications to enable production, registration and sale in pharmacies. According to Kaya Mind, the market has grown substantially – 96% from 2022 to 2023, reaching $140M and is expected to double in 2024 with the distribution of products by the government and entry of big-pharma companies.
“It is the first product containing THC manufactured in Brazil approved by Anvisa, which will help patients with different diseases. The approval was possible because of our strict safety and quality standards, our team’s outstanding technical expertise and our agility,” explains Gustavo Palhares, Ease Labs CEO and co-founder. According to him, until now, patients were relying exclusively on imported products that are sold at much higher prices.
The full-spectrum Cannabis extract preserves various components of the plant and brings a variety of phytocannabinoids in addition to CBD and THC. The product was approved at all safety and quality tests required within GMP standards, at affordable prices – lower than currently practiced, with imported extracts – with discounts representing a reduction between 40% and 70%.
“Scientific studies indicate that Cannabis extracts can bring benefits in conditions such as fibromyalgia, dementia and chronic pain,” says Flávia Guimarães, head of the Scientific Intelligence (SI) area at Ease Labs, who highlights that the doctor will always be responsible for prescribing the treatment.
This is the third product approved in Brazil by Ease Labs. In 2023, the company started selling CBD isolate in pharmacies across the country – It currently sells the product in more than 4K, in 27 states.
CONTACT:
Giuliana Gonçalves
e-mail: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/first-cannabis-full-spectrum-product-manufactured-in-brazil-by-ease-labs-is-approved-by-the-local-health-regulatory-agency-302043583.html
first
In a first for the CBD industry, TRIP officially becomes a ‘Great Taste Producer’, awarded by the UK’s largest and most trusted food and drink awards
LONDON, Aug. 10, 2023 /PRNewswire/ — TRIP continues to break new ground for the CBD industry by becoming the first brand in the category to be awarded with the esteemed title of Great Taste Producer by the Guild of Fine Food. All of TRIP drinks have won Great Taste awards and TRIP has now won in three individual years, leading to the Great Taste producer accolade.
Great Taste judges celebrated the “deliciously refreshing” botanical blends, which has been a key driver of TRIP’s mainstream adoption across the country. TRIP was founded with a mission to destigmatise the conversation around mental health and help millions of people #findtheircalm with delicious, game-changing, authentically functional drinks. The brand has been recognised as the “Soft Drink of the Year” by The Grocer after becoming the fastest growing soft drink in the UK (Nielsen IQ). TRIP has been a viral sensation, drawing in millions of fans with over 50m impressions on tiktok and instagram in January alone, attracting the most organic search traffic of any CBD Drinks brand globally (source: SEMRUSH).
For TRIP to be recognised against soft drinks, cocktails and alcohol alternatives is an exciting milestone in the movement the brand has created to allow people to reach for CBD to destress and unwind, whenever and wherever they need it most. TRIP boasts unique flavours with floral, herbal and citrus notes. Each flavour is packed with calming adaptogens such as ginseng, lemon balm, turmeric and chamomile. Combined with premium CBD TRIP has created an effective, functional drink that has fostered mass adoption and leading repeat rates; 94% of TRIP buyers said they would recommend it to a friend (2022 TRIP consumer survey). In the UK TRIP has 88% market share of CBD drinks (Source: Nielsen IQ) and is now the world’s #1 CBD drink with twice the sales of the #2 brand from the USA (Nielsen IQ).
But why the sudden demand? Studies show that people are increasingly giving up drinking, and since most alcohol alternatives generally don’t have the same calming effect, only TRIP can help people relax in a similar way, unwinding without the threat of a hangover hours later. In particular, Gen Z have made the big switch. In fact, among Generation Z – the most likely age group to be teetotal – 1 in 2 have now tried a CBD drink (Source: KAM Media and Drinkaware).
The other reason people are turning to TRIP is a renewed focus on mental wellbeing among the chaos of everyday life. Millions already find calm through the functionality of CBD drinks but to give extra support to the community at the most stressful time of the year (Source: WIRED).
Find out more at drink-trip.com
-
Cannabis1 week agoMikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks agoIM Cannabis Reports First Quarter Financial Results
-
Innocan1 week agoInnocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis6 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis6 days agoGlobal Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
SCHWAZZE4 days agoSchwazze Announces First Quarter 2024 Financial Results
-
Cannabis4 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis5 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
